223 related articles for article (PubMed ID: 33416163)
1. Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition.
Yang X; Gao Y; Liu Q; Wan L; Liu H; Bian W; Du Y; Huang C
Oncol Rep; 2021 Feb; 45(2):459-468. PubMed ID: 33416163
[TBL] [Abstract][Full Text] [Related]
2. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
3. Triptolide inhibits epithelial‑mesenchymal transition and induces apoptosis in gefitinib‑resistant lung cancer cells.
Li F; Cui H; Jin X; Gong X; Wang W; Wang J
Oncol Rep; 2020 May; 43(5):1569-1579. PubMed ID: 32323848
[TBL] [Abstract][Full Text] [Related]
4. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
Cao W; Liu Y; Zhang R; Zhang B; Wang T; Zhu X; Mei L; Chen H; Zhang H; Ming P; Huang L
Sci Rep; 2015 Jul; 5():8477. PubMed ID: 26166037
[TBL] [Abstract][Full Text] [Related]
5. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.
Feng C; Liu X; Li X; Guo F; Huang C; Qin Q; Wang Y
Oncol Rep; 2016 Jun; 35(6):3460-70. PubMed ID: 27109760
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
9. Silencing of
Zhang P; Li Z; Yang G
Int J Mol Med; 2021 Dec; 48(6):. PubMed ID: 34713300
[TBL] [Abstract][Full Text] [Related]
10. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
Zhu H; Cheng H; Ren Y; Liu ZG; Zhang YF; De Luo B
Mol Biol Rep; 2012 Apr; 39(4):4971-9. PubMed ID: 22160570
[TBL] [Abstract][Full Text] [Related]
12. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
13. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
14. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
Xiao Z; Li M; Zhang X; Rong X; Xu H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
[TBL] [Abstract][Full Text] [Related]
15. The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.
Du W; Sun L; Liu T; Zhu J; Zeng Y; Zhang Y; Wang X; Liu Z; Huang JA
Oncol Rep; 2020 Jul; 44(1):185-195. PubMed ID: 32319651
[TBL] [Abstract][Full Text] [Related]
16. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.
Yu B; Zheng L; Tang H; Wang W; Lin Y
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396444
[TBL] [Abstract][Full Text] [Related]
17. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
Xu L; Meng X; Xu N; Fu W; Tan H; Zhang L; Zhou Q; Qian J; Tu S; Li X; Lao Y; Xu H
Cell Death Dis; 2018 Feb; 9(3):262. PubMed ID: 29449529
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
Sudo M; Chin TM; Mori S; Doan NB; Said JW; Akashi M; Koeffler HP
Cancer Chemother Pharmacol; 2013 May; 71(5):1325-34. PubMed ID: 23515752
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 Fatty Acid-Enriched Fish Oil and Selenium Combination Modulates Endoplasmic Reticulum Stress Response Elements and Reverses Acquired Gefitinib Resistance in HCC827 Lung Adenocarcinoma Cells.
Liao CH; Tzeng YT; Lai GM; Chang CL; Hu MH; Tsai WL; Liu YR; Hsia S; Chuang SE; Chiou TJ; Wang LM; Whang-Peng J; Yao CJ
Mar Drugs; 2020 Jul; 18(8):. PubMed ID: 32751169
[TBL] [Abstract][Full Text] [Related]
20. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
